Last reviewed · How we verify
UBT251
At a glance
| Generic name | UBT251 |
|---|---|
| Sponsor | The United Bio-Technology (Hengqin) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity (PHASE2)
- UBT251 Injection Phase II Clinical Study (CKD) (PHASE2)
- A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) (PHASE2)
- UBT251 Injection Phase II Study (Overweight or Obesity) (PHASE2)
- UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UBT251 CI brief — competitive landscape report
- UBT251 updates RSS · CI watch RSS
- The United Bio-Technology (Hengqin) Co., Ltd. portfolio CI